ClinicalTrials.gg
TerminatedNCT03892889Updated Sep 5, 2021Results posted

A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®

A Phase 3 interventional study of Abilify MyCite® in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Terminated at 68 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-09-05.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Health services research

Why this study was terminated
Study has stopped for having met the primary endpoint.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
277
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 126 studies testing aripiprazole in Schizophrenia — 4 open to participants now, 4 under way, 1 of them phase 3. Aripiprazole · Schizophrenia.

Enrollment
38th of 125
277 · median 130
Started
2019
with 5 others
Phase 3
34 of 126
1 open now
Registered
117th of 126
by date
Lead sponsor
44 of 126
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 126 studies testing aripiprazole in Schizophrenia, this one is the 38th largest by enrollment of the 125 interventional ones that give a count, is one of 6 that started in 2019, is one of 34 in phase 3, and was the 117th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 126 studies testing aripiprazole in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About aripiprazole

Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies testing aripiprazole in Schizophrenia, or all of them as a file.
02

Study summary

To compare inpatient psychiatric hospitalization rates while participants are on oral standard-of-care antipsychotic treatment and later switched to Abilify MyCite®.

Read the detailed description

This study is designed to assess the difference between inpatient psychiatric hospitalization rates in participants on oral standard-of-care antipsychotic treatment(s) for a period of 6 months followed by a switch to Abilify MyCite® for a period of 3 months (Months 1 to 3).

At the Month 3 visit, the investigator should decide if participants will continue on Abilify MyCite® for an additional 3 months (Months 4 to 6) or switch to a standard-of-care treatment for the duration of treatment.

Participants must have had at least 1 inpatient psychiatric hospitalization within 4 years (48 months) and must have been prescribed oral antipsychotics for at least 6 months or longer prior to screening.

Participants will enter a screening period (up to 45 days). If deemed eligible to participate, participants will enter an open-label Abilify MyCite® treatment prospective phase for up to 6 months.

All participants who complete or withdraw from the trial while on Abilify MyCite® will receive a telephone call for safety follow-up approximately 30 days after their last trial visit.

The trial will be conducted at 75 sites in the United States, 493 participants will be screened in order to enroll 320 participants and complete 224 participants. There was an interim analysis planned for the study.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be willing and able to give written , adhere to trial procedures and able to read and understand English.
  • Male and female participants 18 to 65 years of age.
  • Participants must possess a smartphone and is familiar with its use and is willing to download and interact with the Abilify MyCite® app. Participants with a smartphone, that is not compatible with the Abilify MyCite® app will be offered a loaner phone for the trial period.
  • Clinical diagnosis of schizophrenia and able to ingest oral medication.
  • Positive and Negative Syndrome Scale (PANSS) total score between 60-90.
  • Participants currently prescribed oral atypical antipsychotic medication including aripiprazole or appropriate for aripiprazole treatment for 6 months or longer.
  • Participants are required to have had an inpatient hospitalization for schizophrenia within the last 48 months prior to entering the trial.
  • Skin on the anterior chest just above the lower edge of the rib cage that is free of any dermatological problems.

Exclusion criteria

Exclusion Criteria:

  • Females who are breast-feeding and/or who are pregnant.
  • Sexually active males or women of (WOCBP) who do not agree to practice 2 different methods of or remain abstinent during the trial and for 30 days after the last dose of Abilify MyCite®.
  • Any participants who participated in another clinical trial within 30 days of enrollment.
  • Participants who are currently being treated with an LAI antipsychotic or have been treated with an LAI in the retrospective 6-month phase.
  • Participants with a current diagnosis other than schizophrenia.
  • Participants with a known allergy to adhesive tape or any pertinent components of the patch or aripiprazole tablet embedded with an IEM sensor.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
277 participants (actual)

Study arms

  • Experimental
    Abilify MyCite®

    Participants received Abilify MyCite® a combination product of aripiprazole tablet embedded with sensor and wearable patch for 3 months (Months 1 to 3) and continued for an additional 3 months (Months 4 to 6) as per investigators assessment or switch to a standard-of-care treatment of oral atypical antipsychotics or a long acting injectable.

    Combination Product: Abilify MyCite®

Interventions

  • Combination productAbilify MyCite®

    Combination product of aripiprazole tablet embedded with sensor and wearable patch.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Inpatient Psychiatric Hospitalization

    Percentage of participants with inpatient psychiatric hospitalization in Prospective Period With at least one hospitalization in Retrospective Period.

    Time frame: Retrospective Period [Month -6 to Baseline (Day 1)] up to Prospective Period (Day 1 to Month 3)

Secondary outcomes

  1. Percentage of Days With Improved Adherence

    Improved adherence was based on the overall proportion of days covered (PDC) in participants compliant with study drug administration in the Prospective period on Prospective Abilify MyCite® versus Retrospective Period on oral atypical antipsychotics. PDC was calculated as = number of days 'covered' in the Respective Period/number of days in the period \* 100.

    Time frame: Retrospective Period [-1 to -3 months prior to Baseline (Day 1)] up to Prospective Period (1 to 3 months)

07

Results

Posted Sep 5, 2021

Participant flow

Participants took part in the study at 58 investigative sites in the United States from 29 April 2019 to 12 August 2020.

Participant flow — Overall Study
MilestoneAbilify MyCite®
Started277
Completed73
Not completed204
Withdrew: Adverse event17
Withdrew: Lack of efficacy1
Withdrew: Lost to follow-up46
Withdrew: Non-compliance with study drug22
Withdrew: Pregnancy1
Withdrew: Protocol deviation3
Withdrew: Withdrawal by subject50
Withdrew: Withdrawal by caregiver1
Withdrew: Study terminated by sponsor50
Withdrew: Physician decision8
Withdrew: Reason not specified5

Outcome measures

PrimaryPercentage of Participants With Inpatient Psychiatric Hospitalization

Percentage of participants with inpatient psychiatric hospitalization in Prospective Period With at least one hospitalization in Retrospective Period.

Time frame:
Retrospective Period [Month -6 to Baseline (Day 1)] up to Prospective Period (Day 1 to Month 3)
Reported as:
Number · percentage of participants
Percentage of Participants With Inpatient Psychiatric Hospitalization
percentage of participantsAbilify MyCite®
Percentage of Participants With Inpatient Psychiatric Hospitalization0.0
SecondaryPercentage of Days With Improved Adherence

Improved adherence was based on the overall proportion of days covered (PDC) in participants compliant with study drug administration in the Prospective period on Prospective Abilify MyCite® versus Retrospective Period on oral atypical antipsychotics. PDC was calculated as = number of days 'covered' in the Respective Period/number of days in the period \* 100.

Time frame:
Retrospective Period [-1 to -3 months prior to Baseline (Day 1)] up to Prospective Period (1 to 3 months)
Reported as:
Mean · percentage of days
Percentage of Days With Improved Adherence
percentage of daysAbilify MyCite®
PDC in Retrospective Period51.0 ± 37.9
PDC in Prospective Period77.5 ± 31.8
Statistical analysis
  • Abilify MyCite® · paired t-test · p = <0.0001 (Paired t-test was used based on the prospective phase efficacy sample when applicable.)

Adverse events

Collected over Up to 6 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Abilify MyCite®1/277 (0.4%)6/277 (2.2%)0/277 (0%)
Most frequent serious events
Most frequent serious events
EventAbilify MyCite®
SchizophreniaPsychiatric disorders2/277
Pancreatitis AcuteGastrointestinal disorders1/277
Drug HypersensitivityImmune system disorders1/277
Pneumonia BacterialInfections and infestations1/277
Cerebrovascular AccidentNervous system disorders1/277

Baseline characteristics

Intent-to-Treat (ITT) Sample included all enrolled sample who met the study inclusion/exclusion criteria and who are intended to receive study medication in the Prospective Phase.

Age, Continuous
Age, Continuous(Years)Abilify MyCite®
Mean44.2 ± 12.4
Sex: Female, Male
Sex: Female, Male(Participants)Abilify MyCite®
Female95
Male182
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Abilify MyCite®
Hispanic or Latino52
Not Hispanic or Latino223
Unknown or Not Reported2
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Abilify MyCite®
American Indian or Alaska Native4
Asian5
Native Hawaiian or Other Pacific Islander0
Black or African American167
White98
More than one race0
Unknown or Not Reported3
08

Study locations

68 sites
  • Alea Research
    Phoenix, Arizona 85012, United States
  • Woodland International Research Group
    Little Rock, Arkansas 72211, United States
  • ADVANCED RESEARCH CENTER, Inc.
    Anaheim, California 92805, United States
  • CITrials
    Bellflower, California 90706, United States
  • Synexus
    Cerritos, California 90703, United States
  • CMB Clinical Trials
    Colton, California 92324, United States
  • ProScience Research Group
    Culver City, California 90230, United States
  • Collaborative Neuroscience Network, LLC
    Garden Grove, California 92845, United States
  • Behavioral Research Specialists, LLC
    Glendale, California 91206, United States
  • San Fernando Mental Health Center
    Granada Hills, California 91344, United States
  • Om Research LLC
    Lancaster, California 93534, United States
  • Synergy San Diego
    Lemon Grove, California 91945, United States
  • CalNeuro Research Group
    Los Angeles, California 90024, United States
  • Pacific Research Partners
    Oakland, California 94607, United States
  • Excell Research, Inc
    Oceanside, California 92056, United States
  • CNRI-Los Angeles
    Pico Rivera, California 90660, United States
  • Prospective Research Innovations Inc.
    Rancho Cucamonga, California 91730, United States
  • CITrials
    Riverside, California 92506, United States
  • CNRI-San Diego, LLC
    San Diego, California 92102, United States
  • Artemis Institute for Clinical Research
    San Diego, California 92103, United States
  • CITrials, Inc.
    Santa Ana, California 92705, United States
  • Siyan Clinical Research
    Santa Rosa, California 95401, United States
  • Collaborative Neuroscience Network, LLC
    Torrance, California 90502, United States
  • Sarkis Clinical Trials
    Gainesville, Florida 32607, United States
  • Indago Research & Health Center, Inc.
    Hialeah, Florida 33012, United States
  • New Life medical Research Inc.
    Hialeah, Florida 33012, United States
  • Galiz Research
    Hialeah, Florida 33016, United States
  • Innovative Clinical Research, Inc.
    Lauderhill, Florida 33319, United States
  • Premier Clinical Research Institute Inc.
    Miami, Florida 33122, United States
  • CCM Clinical Research Group
    Miami, Florida 33133, United States
  • Prestige Clinical Research Center Inc.
    Miami, Florida 33133, United States
  • Stedman Clinical Tirlas
    Tampa, Florida 33613, United States
  • Nova Psychiatry, Inc
    Winter Park, Florida 32789, United States
  • Emory
    Atlanta, Georgia 30303, United States
  • Synexus Clinical Research US
    Atlanta, Georgia 30328, United States
  • iResearch Atlanta
    Decatur, Georgia 30030, United States
  • iResearch Savannah
    Savannah, Georgia 31405, United States
  • Uptown Research Institute
    Chicago, Illinois 60640, United States
  • AMITA Health
    Hoffman Estates, Illinois 60169, United States
  • SIU School of Medicine
    Springfield, Illinois 62702, United States
  • Lake Charles Clinical Trial
    Lake Charles, Louisiana 70629, United States
  • Michigan Clinical Research Institute
    Ann Arbor, Michigan 48108, United States
  • Precise Research Centers
    Flowood, Mississippi 39232, United States
  • Arch Clinical Trials, LLC
    Saint Louis, Missouri 63118, United States
  • PsychCare Consultants Research
    Saint Louis, Missouri 63128, United States
  • Alivation Research, LLC.
    Lincoln, Nebraska 68526, United States
  • Altea Research Institute
    Las Vegas, Nevada 89102, United States
  • Kolade Research Institute/Cal Psychiatric Services
    Las Vegas, Nevada 89109, United States
  • Hassman Research Institute
    Berlin, New Jersey 08009, United States
  • Synexus US
    Jamaica, New York 11432, United States
  • Manhattan Psychiatric Center
    New York, New York 10035, United States
  • Manhattan Behavioral Medicine PLLC
    New York, New York 10036, United States
  • Finger Lakes Clinical Research
    Rochester, New York 14618, United States
  • Richmond Behavioral Associates
    Staten Island, New York 10312, United States
  • Midwest Clinical Research Center
    Dayton, Ohio 45417, United States
  • Signature Research Associates Inc
    Fairlawn, Ohio 44333, United States
  • Charak Clinical research Center
    Garfield Heights, Ohio 44125, United States
  • Neuro-Behavioral Clinical Research, Inc.
    North Canton, Ohio 44720, United States
  • The Rivus Wellness & Research Institute
    Oklahoma City, Oklahoma 73112, United States
  • Cutting Edge Research Group
    Oklahoma City, Oklahoma 73116, United States
  • Suburban Research Associates
    Media, Pennsylvania 19063, United States
  • Psychiatric Consultants, PC
    Franklin, Tennessee 37067, United States
  • Community Clinical Research, Inc.
    Austin, Texas 78754, United States
  • InSite Clinical Research
    DeSoto, Texas 75115, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Pillar Clinical Research
    Richardson, Texas 75080, United States
  • Noetic Psychiatry
    Springville, Utah 84663, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
09

References and documents

Publications

  • Cohen EA, Skubiak T, Hadzi Boskovic D, Norman K, Knights J, Fang H, Coppin-Renz A, Peters-Strickland T, Lindenmayer JP, Reuteman-Fowler JC. Phase 3b Multicenter, Prospective, Open-label Trial to Evaluate the Effects of a Digital Medicine System on Inpatient Psychiatric Hospitalization Rates for Adults With Schizophrenia. J Clin Psychiatry. 2022 Apr 11;83(3):21m14132. doi: 10.4088/JCP.21m14132. PubMed 35421287 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com

Data sharing details ↗ · clinical-trials.otsuka.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2019 to primary completion in Aug 2020, 15 months.

Results were first posted in Sep 2021, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2019
First posted
Mar 27, 2019
StartActual
Apr 29, 2019
Primary completionActual
Aug 12, 2020
CompletionActual
Sep 29, 2020
Results first posted
Sep 5, 2021
Last update
Sep 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03892889
Responsible party
Sponsor
First posted
Mar 27, 2019
Start date
Apr 29, 2019
Primary completion
Aug 12, 2020
Completion
Sep 29, 2020
Results posted
Sep 5, 2021
Last update
Sep 5, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion